CORRECTION
Pfizer Licenses Out Compounds to Research Supply Company
An Abcam spokesperson told Outsourcing-Pharma.com: “Pfizer are a leading research-based pharmaceutical company and we are proud to offer their products within our portfolio.
“This agreement gives our customers access to a diverse group of sought after research compounds”
The compounds – which include atorvastatin, doxorubicin, nifedipine and bosutinib – add to a number of products the company has acquired through licensing agreements, with Eli Lilly, the NIH and the University of Columbia on its books.
They will be used in a number of research fields including neuroscience, cardiovascular disease, cancer and antibiotic resistance.
